Phase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 16, 2019

Primary Completion Date

October 13, 2022

Study Completion Date

October 13, 2022

Conditions
Advanced Tumors
Interventions
DRUG

CDP1

"Single dose part:~Cohort 1:400 mg/m2; Cohort 2: 500 mg/m2; Cohort 3: 750 mg/m2;~Multi-dose Part:~Starting dose: Cohort 1:400 mg/m2; Cohort 2/3: 500 mg/m2; Maintenance dose: Cohort 1:250 mg/m2, QW; Cohort 2/3: 500 mg/m2, Q2W;"

DRUG

CDP1

Starting dose: 400 mg/m2; Maintenance dose: 250 mg/m2,QW;

DRUG

TIP chemotherapy

Paclitaxel: 175 mg/m2 in day 1, Q3W; Ifosfamide: 1200 mg/m2 in day 1, day 2 and day 3, Q3W; Cisplatin: 25 mg/m2 in day 1, day 2 and day 3, Q3W; Participants received TIP chemotherapy up to 6 cycles (21 days per cycle).

Trial Locations (1)

Unknown

Dragonboat Biopharmaceutical,Co.,Ltd, Shanghai

All Listed Sponsors
lead

Dragonboat Biopharmaceutical Company Limited

INDUSTRY